Histone acetylation patterns of typical and atypical pituitary adenomas indicate epigenetic shift of these tumours

Journal of Neuroendocrinology

Volumn 23, Issue 6, 2011, Pages 525-530

  Ebrahimi, A ^a   Schittenhelm, J ^a   Honegger, J ^b   Schluesener, H J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Epigenetics; Histone 3 lysine 9; Histone acetylation; Pituitary adenoma

Indexed keywords

BIOLOGICAL MARKER; HISTONE; HISTONE 3 LYSINE 9; MONOCLONAL ANTIBODY KI 67; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CHROMATIN; EPIGENETICS; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSCOPY; PRIORITY JOURNAL; PROMOTER REGION; TUMOR CLASSIFICATION;

ACETYLATION; ADENOMA; DISEASE PROGRESSION; EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PITUITARY NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79955975059     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2011.02129.x     Document Type: Article

References (40)

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004: 10-47.
2. Kovacs K, Horvath E. Tumours of the pituitary gland. In: Hartmann WH, Sobin LH, eds. Atlas of Tumor Pathology, Fascicle 21, Series II. Washington, DC: AFPI, 1986: 1-264.
3. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990; 71: 1427-1433.
4. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr, Lloyd RV. Pituitary carcinoma: a clinicopathological review. J Neurosurg 2005; 56: 1066-1074.
5. Kontogeorgos G. Predictive markers of pituitary adenoma behavior. Neuroendocrinology 2006; 83: 179-188.
6. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005; 90: 3089-3099.
7. Fouse SD, Costello JF. Epigenetics of neurological cancers. Future Oncol 2009; 5: 1615-1629.
8. Wu Ct, Morris JR. Genes, genetics, and epigenetics: a correspondence. Science 2001; 293: 1103-1105.
9. Hegi ME, Sciuscio D, Murat A, Levivier M, Stupp R. Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res 2009; 15: 5026-5031.
10. Nagarajan RP, Costello JF. Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics 2009; 6: 436-346.
11. Farrell WE, Clayton RN. Epigenetic change in pituitary tumourigenesis. Endocr Relat Cancer 2003; 10: 323-330.
12. Farrell WE. Epigenetic mechanisms of tumourigenesis. Horm Metab Res 2005; 37: 361-368.
13. Ezzat S. Epigenetic control in pituitary tumours. Endocr J 2008; 55: 951-957.
14. Liu CL, Kaplan T, Kim M, Buratowski S, Schreiber SL, Friedman N, Rando OJ. Single nucleosome mapping of histone modifications in S. cerevisiae. PLoS Biol 2005; 3: 328.
15. Pokholok DK, Harbison CT, Levine S, Cole M, Hannett NM, Lee TI, Bell GW, Walker K, Rolfe PA, Herbolsheimer E, Zeitlinger J, Lewitter F, Gifford DK, Young RA. Genome wide map of nucleosome acetylation and methylation in yeast. Cell 2005; 122: 517-527.
16. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, Zhao K. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008; 40: 897-903.
17. MacDonald VE, Howe LJ. Histone acetylation: where to go and how to get there. Epigenetics 2009; 4: 139-143.
18. Rosaleny LE, Ruiz-Garcia AB, Garcia-Martinez J, Perez-Ortin JE, Tordera V. The Sas3p and Gcn5p histone acetyltransferases are recruited to similar genes. Genome Biol 2007; 8: 119.
19. Sawan C, Herceg Z. Histone modifications and cancer. Adv Genet 2010; 70: 57-85.
20. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M, Croce CM, Fusco A. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002; 21: 3190-3198.
21. Fedele M, Pierantoni GM, Visone R, Fusco A. Critical role of the HMGA2 gene in pituitary adenomas. Cell Cycle 2006; 5: 2045-2048.
22. Schittenhelm J, Reifenberger G, Ritz R, Naegele T, Weller M, Pantazis G, Capper D, Beschorner R, Meyermann R, Mittelbronn M. Primary anaplastic ganglioglioma with a small-cell glioblastoma component. Clin Neuropathol 2008; 27: 91-95.
23. Marmorstein R, Roth SY. Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev 2001; 11: 155-161.
24. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
25. Yoshioka H, Shirayoshi Y, Oshimura M. A novel in vitro system for analyzing parental allele-specific histone acetylation in genomic imprinting. J Hum Genet 2001; 46: 626-632.
26. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003; 983: 84-100.
27. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 2008; 68: 1-11.
28. Ezzat S, Yu S, Asa SL. Ikaros isoform in human pituitary tumours: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter. Am J Pathol 2003; 163: 1177-1184.
29. Ferry AL, Locasto DM, Meszaros LB, Bailey JC, Jonsen MD, Brodsky K, Hoon CJ, Gutierrez-Hartmann A, Diamond S. Pit-1 beta reduces transcription and CREB-binding protein recruitment in a DNA context-dependent manner. J Endocrinol 2005; 185: 173-185.
30. Dudley KJ, Revill K, Clayton RN, Farrell WE. Pituitary tumours: all silent on the epigenetics front. J Mol Endocrinol 2009; 42: 461-468.
31. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3 and -A12 in human cancer cells. Mol Cancer Res 2006; 4: 339-349.
32. Zhu X, Asa SL, Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin Cancer Res 2008; 14: 1984-1996.
33. Zhu X, Mao X, Hurren R, Schimmer AD, Ezzat S, Asa SL. Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. J Clin Endocrinol Metab 2008; 93: 3610-3617.
34. Ezzat S, Zhu X, Loeper S, Fischer S, Asa SL. Tumour derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells. Mol Endocrinol 2006; 20: 2976-2986.
35. Sangeetha SR, Singh N, Vender JR, Dhandapani KM. Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells. Endocrine 2009; 35: 389-396.
36. Dehan P, Kustermans G, Guenin S, Horion J, Boniver J, Delvenne P. DNA methylation and cancer diagnosis: new methods and applications. Expert Rev Mol Diagn 2009; 9: 651-657.
37. Gerdes J, Lemke H, Baisch H, Wacker HH, Schab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715.
38. Thapar K, Scheithauer B, Kovacs K, Pernicone PJ, Laws ER Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 1996; 38: 765-769.
39. Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, Horvath E, Kovacs K, Kuroki T, Young WF Jr, Sebo TJ, Riehle DL, Belzberg AJ. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg 2002; 96: 352-360.
40. Ragel B, Couldwell W. Pituitary carcinoma: a review of the literature. Neurosurg Focus 2004; 16: E7.